Impaired beta cell function is present in nondiabetic rheumatoid arthritis patients

Arthritis Research and Therapy

Volumn 15, Issue 1, 2013, Pages

  Ferraz Amaro, Iván ^a   García Dopico, Jose A ^a   Medina Vega, Lilian ^a   González Gay, Miguel A ^b   Díaz González, Federico ^a,c  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOCORTICOID; INSULIN; PREDNISONE; PROINSULIN;

ADULT; ARTICLE; BETA CELL; CARDIOVASCULAR RISK; CELLS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLITE; RHEUMATOID ARTHRITIS; COMPLICATION; MIDDLE AGED; PANCREAS ISLET BETA CELL; PATHOLOGY;

ADULT; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED;

EID: 84872440686     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4149     Document Type: Article

References (35)

1. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008, 59:1690-1697. 10.1002/art.24092, 19035419.
2. Meune C, Touze E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2009, 48:1309-1313.
3. Ferraz Amaro I, Diaz Gonzalez F, Gonzalez Juanatey C, Gonzalez Gay MA. [Insulin resistance and rheumatoid arthritis]. Reumatol Clin 2007, 7:124-129.
4. Wasko MC, Kay J, Hsia EC, Rahman MU. Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. Arthritis Care Res (Hoboken) 2011, 63:512-521.
5. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Llorca J. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Ann N Y Acad Sci 2010, 1193:153-159. 10.1111/j.1749-6632.2009.05287.x, 20398022.
6. Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 2002, 4:R5. 10.1186/ar428, 125299, 12223108.
7. Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, Sokka T, Raggi P, Pincus T, Stein CM. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008, 58:2105-2112. 10.1002/art.23600, 2755593, 18576352.
8. Moller DE, Flier JS. Insulin resistance: mechanisms, syndromes, and implications. N Engl J Med 1991, 325:938-948. 10.1056/NEJM199109263251307, 1881419.
9. Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 2008, 14:222-231. 2215762, 18235842.
10. Shahin D, Eltoraby E, Mesbah A, Houssen M. Insulin resistance in early untreated rheumatoid arthritis patients. Clin Biochem 2010, 43:661-665. 10.1016/j.clinbiochem.2010.01.012, 20144599.
11. O'Rahilly S, Gray H, Humphreys PJ, Krook A, Polonsky KS, White A, Gibson S, Taylor K, Carr C. Brief report: impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. N Engl J Med 1995, 333:1386-1390. 10.1056/NEJM199511233332104, 7477119.
12. Kahn SE, Halban PA. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 1997, 46:1725-1732. 10.2337/diabetes.46.11.1725, 9356018.
13. Roder ME, Dinesen B, Hartling SG, Houssa P, Vestergaard H, Sodoyez-Goffaux F, Binder C. Intact proinsulin and beta-cell function in lean and obese subjects with and without type 2 diabetes. Diabetes Care 1999, 22:609-614. 10.2337/diacare.22.4.609, 10189540.
14. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580-1588.
15. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48. 10.1002/art.1780380107, 7818570.
16. Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 1999, 42:2220-2230. 10.1002/1529-0131(199910)42:10<2220::AID-ANR26>3.0.CO;2-5, 10524697.
17. Adult Treatment Panel III Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults. JAMA 2001, 285:2486-2497. 10.1001/jama.285.19.2486, 11368702, Adult Treatment Panel III.
18. The HOMA calculator. , http://www.dtu.ox.ac.uk/homacalculator/index.php
19. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998, 21:2191-2192. 10.2337/diacare.21.12.2191, 9839117.
20. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495. 10.2337/diacare.27.6.1487, 15161807.
21. Loopstra-Masters RC, Haffner SM, Lorenzo C, Wagenknecht LE, Hanley AJ. Proinsulin-to-C-peptide ratio versus proinsulin-to-insulin ratio in the prediction of incident diabetes: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetologia 2011, 54:3047-3054. 10.1007/s00125-011-2322-2, 21959959.
22. Svenson KL, Lundqvist G, Wide L, Hallgren R. Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones. Metabolism 1987, 36:940-943. 10.1016/0026-0495(87)90128-4, 3309545.
23. Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006, 54:2765-2775. 10.1002/art.22053, 16947779.
24. Bregenzer N, Hartmann A, Strauch U, Scholmerich J, Andus T, Bollheimer LC. Increased insulin resistance and beta cell activity in patients with Crohn's disease. Inflamm Bowel Dis 2006, 12:53-56. 10.1097/01.MIB.0000195975.97673.f5, 16374259.
25. Haffner SM, Gonzalez C, Mykkanen L, Stern M. Total immunoreactive proinsulin, immunoreactive insulin and specific insulin in relation to conversion to NIDDM: the Mexico City Diabetes Study. Diabetologia 1997, 40:830-837. 10.1007/s001250050756, 9243105.
26. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 2002, 32(Suppl 3):35-45.
27. Weaver JR, Holman TR, Imai Y, Jadhav A, Kenyon V, Maloney DJ, Nadler JL, Rai G, Simeonov A, Taylor-Fishwick DA. Integration of pro-inflammatory cytokines, 12-lipoxygenase and NOX-1 in pancreatic islet beta cell dysfunction. Mol Cell Endocrinol 2012, 358:88-95. 10.1016/j.mce.2012.03.004, 22502743.
28. Kim S, Kim KA, Suk K, Kim YH, Oh SH, Lee MK, Kim KW, Lee MS. Apoptosis of human islet cells by cytokines. Immune Netw 2012, 12:113-117. 10.4110/in.2012.12.3.113, 3422709, 22916047.
29. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007, 356:1517-1526. 10.1056/NEJMoa065213, 17429083.
30. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, Kaiser N, Halban PA, Donath MY. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002, 110:851-860. 151125, 12235117.
31. Dessein PH, Joffe BI, Stanwix A, Botha AS, Moomal Z. The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J Rheumatol 2002, 29:462-466.
32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419. 10.1007/BF00280883, 3899825.
33. Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, Raggi P, Sokka T, Pincus T, Stein CM. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008, 196:756-763. 10.1016/j.atherosclerosis.2007.01.004, 17266963.
34. Giles JT, Allison M, Blumenthal RS, Post W, Gelber AC, Petri M, Tracy R, Szklo M, Bathon JM. Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum 2010, 62:3173-3182. 10.1002/art.27629, 2962724, 20589684.
35. Toms TE, Panoulas VF, Douglas KM, Griffiths HR, Kitas GD. Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 2008, 10:R145. 10.1186/ar2578, 2656250, 19091101.